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RESEARCH ARTICLE
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ABSTRACT
Evidence has been accumulating to indicate that extracellular vesicles (EVs), including exosomes,
released by cancer cells can foster tumour progression. The molecular chaperones – CDC37,
HSP90α and HSP90β play key roles in cancer progression including epithelial-mesenchymal
transition (EMT), although their contribution to EVs-mediated cell–cell communication in tumour
microenvironment has not been thoroughly examined. Here we show that triple depletion of the
chaperone trio attenuates numerous cancer malignancy events exerted through EV release.
Metastatic oral cancer-derived EVs (MEV) were enriched with HSP90α HSP90β and cancer-
initiating cell marker CD326/EpCAM. Depletion of these chaperones individually induced com-
pensatory increases in the other chaperones, whereas triple siRNA targeting of these molecules
markedly diminished the levels of the chaperone trio and attenuated EMT. MEV were potent
agents in initiating EMT in normal epithelial cells, a process that was attenuated by the triple
chaperone depletion. The migration, invasion, and in vitro tumour initiation of oral cancer cells
were significantly promoted by MEV, while triple depletion of CDC37/HSP90α/β reversed these
MEV-driven malignancy events. In metastatic oral cancer patient-derived tumours, HSP90β was
significantly accumulated in infiltrating tumour-associated macrophages (TAM) as compared to
lower grade oral cancer cases. HSP90-enriched MEV-induced TAM polarization to an M2 pheno-
type, a transition known to support cancer progression, whereas the triple chaperone depletion
attenuated this effect. Mechanistically, the triple chaperone depletion in metastatic oral cancer
cells effectively reduced MEV transmission into macrophages. Hence, siRNA-mediated knockdown
of the chaperone trio (CDC37/HSP90α/HSP90β) could potentially be a novel therapeutic strategy
to attenuate several EV-driven malignancy events in the tumour microenvironment.
Abbreviations: CDC37: cell division control 37; EMT: epithelial-mesenchymal transmission; EV:
extracellular vesicles; HNSCC: head and neck squamous cell carcinoma; HSP90: heat shock protein
90; TAM: tumour-associated macrophage
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Extracellular vesicles (EVs) are extracellular nano-particles
surrounded by lipid membranes containing a variety of
molecular cargos such as proteins, small and long RNA,
DNA molecules, glycan and metabolites that are secreted
by cells [1,2]. Major EV subtypes are endosome-originated
exosomes and plasma membrane-derived ectosomes (aka
microvesicles or microparticles) while additional types of
EVs consisting of large oncosomes (1–10 μm), matrix
vesicles, migrasomes, exopheres (~4 μm), exomeres
(~35 nm) and bacterial outer membrane vesicles have
been reported [3,4]. EVs can play roles in discarding redun-
dant intracellular materials while also mediating cell–cell
communication when their cargos reached recipient cells/
organs [5,6]. These vesicles also play pivotal roles in influ-
encing the local tumour microenvironment, enter body
CONTACT Takanori Eguchi, eguchi.takanori@gmail.com, 2-5-1, Shikata-cho, Okayama 700-8525 Japan
Supplemental data for this article can be accessed here.
JOURNAL OF EXTRACELLULAR VESICLES
2020, VOL. 9, 1769373
https://doi.org/10.1080/20013078.2020.1769373
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
fluids, and initiate distant organmodifications such as pre-/
pro-metastatic niche formation [5,6]. Recent studies,
including ours, have shown that cancer cell-derived EVs
could also alter the properties of non-cancerous host cells
such as epithelial cells and macrophages, through molecu-
lar transfer [7,8]. Tumour-derived EVs are often enriched
with heat shock proteins (HSPs) [9–12], tetraspanins such
asCD9 andCD63 (aka LAMP3), andCD326 (aka epithelial
cell-adhesion molecule [EpCAM], a marker of cancer-
initiating cells) [1,12,13]. We showed that high-metastatic
oral squamous cell carcinoma cells secrete EVs enriched
withHSP90α, HSP90β, CD326 and CD9 compared to low-
metastatic oral cancer cell-derived EVs [12]. Moreover, the
elevated expression of HSP90 family members was found
to correlate with a poor prognosis for head and neck cancer
cases [12]. Double knockdown of HSP90α and HSP90β,
using small interfering RNA (siRNA) significantly reduced
the survival of highly metastatic oral cancer cells, although
single knockdown of each HSP90 was ineffective [12].
HSP90 is an essential protein in intracellular protein
folding, wound healing and cancer progression [14–
16]. However, more recent studies, including ours,
have revealed the secretion of HSP90, leading to
novel functions in cell–cell communication. More
recently, HSP90 has been found also as a major cargo
contained in EVs [10–12,17]. The HSP90 family con-
sists of four members including the proteotoxic stress-
inducible HSP90α encoded by HSP90AA1, the consti-
tutively expressed HSP90β encoded by HSP90AB1, the
mitochondrially localized TRAP1, and an ER-resident
paralog Gp96 (aka Grp94 or endoplasmin) [12,17].
Notably, HSP90α is often overexpressed in cancer
cells and can be secreted to the extracellular space as
a soluble protein or as a cargo protein of EVs
[10,12,18]. Recently, the EV-proteome analysis of oral
cancer cells has revealed abundant secretion of EVs
enriched with HSP90 from high-metastatic oral cancer
cells [12].
Epithelial-mesenchymal transition (EMT) is a key
biological event potentially regulated by extracellular
HSP90 [19,20]. EMT involves phenotypic changes in
cells from epithelial to mesenchymal properties and
promotes motility [21], migration, invasion, stemness
[22], and drug resistance [23–25] in various types of
cancer cells [26]. Numerous EMT-promoting factors
have been identified, although recent studies, including
ours, have revealed that cancer cell-derived EVs often
initiate EMT in epithelial cells [8,10] and promote
EMT in tumour cells [27]. Notably, cell division con-
trol 37 (CDC37) plays a pivotal role in stabilizing
HSP90 client proteins, thereby facilitating numerous
intracellular oncogenic signalling pathways [14,28–
31]. CDC37 functions primarily in a complex with
both HSP90 paralogs- HSP90α and HSP90β to mediate
the three-dimensional (3D) folding and structural
integrity of client proteins kinases essential for EMT
[32–35]. Moreover, knockdown of CDC37 reduced
cellular proteostasis and release of EV proteins such
as CD9 [10].
Macrophages resident in the tumour microenviron-
ment may play substantial roles in deciding the deli-
cate balance between cancer progression and
suppression. Macrophages are highly heterogeneous
cells that can rapidly change their properties in
response to local microenvironmental signals [36].
The tumour microenvironment often contains infil-
trating tumour-associated macrophages (TAM) that
affect many processes, including tumour initiation,
migration, invasion [37], angiogenesis, metastasis
[38], chemoresistance [39] and immune checkpoint
[40,41]. An elevated number of TAM bearing an M2-
type polarity is associated with a poor prognosis for
cancers [40]. M2-type macrophages play a key role in
adhesion, migration, invasion and cytokine produc-
tion of oral cancer cells favouring tumour growth
[42]. We conjecture that the roles of TAM could be
modified by EV bioactive molecules secreted by
tumour cells.
In the present study, we aimed to examine: (i) if
high-metastatic oral cancer-derived EVs could promote
cancer malignancy properties such as EMT, enhanced
migration, increased invasion, tumour initiation and
macrophage M2 polarization, (ii) if triple depletion of
the chaperone trio – CDC37, HSP90α and HSP90β
could lessen the effects of EVs on tumour progression.
We also aimed to investigate (iii) HSP90 expression
and distribution in tumours, their stroma and in
TAM in different malignancy grades of oral cancer, to




HSC-3, HSC-3-M3, Ca9-22, HO-1-u-1, SAS, HSC-2,
HSC-4 and THP-1 were obtained from JCRB Cell
Bank and maintained in DMEM containing 10% FBS.
An immortalized oral mucosa epithelial cell line RT7
was provided by Dr Nobuyuki Kamata at Hiroshima
University and maintained in KGM-gold (Lonza). For
EV preparation, cells were cultured in serum-free
DMEM. THP-1 was maintained in RPMI-1640 with
10% FBS and for macrophage-like differentiation, sti-
mulated with 200 nM of phorbol 12-myristate 13-
acetate (PMA) for 24 h.
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siRNA transfection
We designed siRNA sequences targeting mRNA of
CDC37, HSP90AA1 or HSP90AB1 (Supplementary
Table 1) [10,12]. For targeting each mRNA, a mixture
of two types of siRNA duplex was used. The control
non-targeting siRNA was purchased from Nippon
Gene. siRNA was transfected as described previously
[10]. Briefly, cells were pre-cultured in DMEM con-
taining 10% FBS for 1 day or until 60–80% confluency
and then transfected with siRNA at a final concentra-
tion of 5 nM using Lipofectamine RNAi MAX
(ThermoFisher). The medium was replaced with
serum-free one at 24 h post-transfection. Cells were
then cultured for 48 h before EV preparation, ATP-
based cell viability assay, and lactate dehydrogenase
release (LDH) assay. For Gluc assay, cell culture super-
natants were collected at 6, 24 and 48 h post-medium
replacement. At the same time points, cells were
detached using Trypsin/EDTA and stained with
Trypan Blue for cell counting. The number of Trypan
Blue-negative and -positive cells were counted.
EV and EV-free fractions
EV fraction and soluble fraction were prepared from
serum-free culture supernatants at 48 h post-medium
replacement using a modified polymer-based precipita-
tion method as described [10,12]. Simultaneously,
whole cell lysates were prepared as described below.
Briefly, cell culture supernatant was centrifuged at
2,000 × g for 30 min at 4°C. The supernatant was
centrifuged at 10,000 × g for 30 min at 4°C. The super-
natants were filtered with a 0.2-μm pore filter in a few
experiments, as shown in supplemental items. The
pass-through was concentrated using an ultrafiltration
device for MW.100 k to separate an EV fraction and
a soluble EV-free fraction. The concentrate was applied
to polymers of Total Exosome Isolation
(ThermoFisher). The pass-through was concentrated
using an ultrafiltration device for MW.10 k and used
as EV-free conditioned media. The EV fractions were
suspended in 100–200 μL PBS (−). For protein assay,
10 μL of 10× RIPA buffer and 100× a protease inhibitor
cocktail (Sigma) were added to the 100 μL of the EV
fraction and incubated on ice for 15 min. Protein
concentration was analysed using micro BCA protein
assay (ThermoFisher).
Whole cell lysate
The whole cell lysate (WCL) was prepared as described
previously [5,10]. Briefly, cells cultured in a 6-cm dish
were lysed in 150–200 μL/dish of a RIPA buffer (1%
NP-40, 0.1% SDS, and 0.5% deoxycholate, and EDTA-
free protease inhibitor cocktail in PBS) and collected by
using a cell scraper. Cells were further lysed by a 25-
gauge syringes for 10 strokes and then incubated for
30 min on ice. The lysate was centrifuged at
12,000 × g for 20 min at 4°C and the supernatant was
used as a WCL. Protein concentration of the WCL was
analysed using micro BCA protein assay
(ThermoFisher).
Western blotting
Western blotting was performed as described
[10,13,43]. The same protein amounts of WCL were
subjected to SDS-PAGE, followed by transfer to
a PVDF membrane using wet- and semi-dry methods
where appropriate. The membranes were blocked in
5% skim milk in Tris-buffered saline containing
0.05% Tween 20 for 60 min, incubated with primary
antibodies, and then incubated with horseradish per-
oxidase (HRP)-conjugated secondary antibodies. For
CD63, blocking was performed in 10% overnight and
the primary antibody was reacted for 2 days. Blots were
visualized with ECL substrate. We used antibodies
against CD9 (MEX001-3, Medical and Biological
Laboratories), CD63 (EXOAB-CD63A-1, System
Biosciences), HSP90α (GTX109753, GeneTex),
HSP90β (GTX101448, GeneTex), MMP9 (ab38898,
Abcam) and HRP-conjugated anti-β-actin antibody
(clone 2F3, Fujifilm/Wako) as optimized previously
[5,8,10,12,23,44]. Antibodies against CD326 (VU1D9),
CDC37 (D11A3), E-cadherin (24E10), β-catenin
(D10A8), Vimentin (D21H3), Snail (C15D3),
Claudin-1 (D5H1D) and COX-4 (3E11) were pur-
chased from Cell Signaling Technology.
We loaded the same protein amount per lane in
each Western blotting experiment. To obtain relative
expression levels, relative band intensities were mea-
sured in the same membrane using ImageJ. The raw
values were converted into relative values as con-
trol = 1.0. For normalization, relative levels of the
protein of interest per loading control were calculated.
Transmission electron microscopy (TEM)
TEM and particle diameter distribution analysis were
carried out as described previously [10,12]. Briefly,
a 400-mesh copper grid coated with formvar/carbon
films was hydrophilically treated. The EV suspension
(5–10 μL) was placed on Parafilm, and the grid was
floated on the EV liquid and left for 15 min. The
sample was negatively stained with 2% uranyl acetate
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solution for 2 min. EVs on the grid were visualized
with 20,000 times magnification with an H-7650 trans-
mission electron microscope (Hitachi, Tokyo, Japan).
Particle size distribution
A part of EV fraction was diluted within PBS (−) to
volume up to 40 μL and then analysed using Zetasizer
nano ZSP (Malvern Panalytical, Malvern, UK) in
a range of 0.3–10,000 nm-diameters, as described
[10,12]. Alternatively, a part of EV fraction was
mixed with PBS (−) to volume up to 250 µL and then
particle diameters of EV fractions were analysed using
ELS-8000 (Otsuka Electronics, Hirakata, Japan)
between 30 and 1000 nano-diameters, as described [8].
Fluorescent ceramide-labelled EV transmission
As described [8,45,46], 20 μg of EV fraction was incubated
with 10 μM BODIPY TR Ceramide (ThermoFisher) for
20 min at 37°C. Excessive dye was removed using
Exosome Spin Columns (MW. 3000) (ThermoFisher).
The labelled EVs were added to the culture medium of
HSC-3 cells in 96-well plates at 25 μg/mL. Cells were fixed
with 4% paraformaldehyde in PBS for 10 min and per-
meabilized with 0.5% Tween-20 in PBS for 5 min. Cells
were incubated with ActinGreen488 (ThermoFisher) for
30 min and with DAPI for 5 min. Fluorescence images of
random four fields were taken using a Floid® Imaging
Station (ThermoFisher) and fluorescence-positive cells in
each field were counted.
EV reporters
The lentiviral reporter constructs of CSCW-
palmitoylation signal-tandem dimer Tomato (palmT),
CSCW-palmitoylation signal-EGFP (palmG) [47] and
CSCW-Gaussia luciferase-biotin acceptor-PDGFR
transmembrane-IRES-GFP (mbGluc) [48] were kindly
gifted from Dr Charles P. Lai. For virus production,
HEK293T cells at 70–80% confluence were transfected
with PalmT or PalmG constructs, psPAX2 packaging
plasmid and pMD2.G envelope plasmid using PEI max
(Polysciences). HSC-3, HSC-3-M3 or THP-1 cells were
infected by using spinfection method with the viral
solution. Infected/transduced stable cells were selected
using puromycin. Isolation of single clones was carried
out by limiting dilution method. We established
palmtdTomato-expressed HSC-3-M3 cells (designated
HSC3M3/palmT), palmGFP-expressed HSC-3-M3 cells
(designated HSC3M3/palmG), palmGFP-expressed
HSC-3 cells (designated HSC3/palmG) and palmGFP-
expressed THP-1 cells (designated THP1/palmG) [46].
Luciferase assay
Gaussia luciferase activities were quantified using
a Gaussia luciferase glow kit (Pierce). Culture super-
natants of cells transfected with siRNA were collected
at 6, 24 and 48 h after the replacement of media. Cell
culture supernatant (10 or 20 μL) were mixed with
50 μL of coelenterazine working solution in a white 96-
well plate. Luminescence was measured in a plate
reader Gemini XP SOK (Molecular Devices).
Confocal laser-scanning microscopy
CLSM was carried out as described previously [5,8,49].
Briefly, recipient cells were seeded on a type I collagen-
coated coverslip in a 24-well plate at a density of
1 × 104 cells per well and cultured for 24 h in a serum-
containing culture media. EVs (HSC3 M3/palmT-EV;
5 μg/mL) or PBS were added to the culture media.
After the incubation for 24 h, cells were fixed with
4% paraformaldehyde in PBS for 10 min.
Fluorescence images were taken using a CLSM system
(LSM 780 META; Carl Zeiss).
Reporter vesicle transmission
As recipients, HSC3/palmG cells or THP1/palmG cells
treated with PMA for 24 h were seeded in a 96-well
plate at a concentration of 1 × 104 cells/well and cul-
tured for 24 h in a serum-containing media. EV frac-
tions (2.5 and 25 μg/mL) or PBS were added to the
culture media. The transmission of the palmT-EVs was
monitored every 1 h for 8 h in ArrayScan High
Content Screening (HCS) System (ThermoFisher).
The fluorescence intensity of each cell was determined
using a filter set (485/594) for (GFP/Tomato). The
fluorescence intensity values less than 85 and 60 were
defined as the background values in recipient HSC3/
palmG and macrophage-like THP1/palmG cells,
respectively, and subtracted from the raw values. The
fluorescence-positive cells were counted in one field
(2,632 μm2). The transmission rate was calculated as
a percent of exogenous palmT-positive cells per
palmG-positive recipient cells with a fluorescence
intensity 35 or more.
Cell viability
Cell viability was measured as described previously
[50–52]. ATP content was quantified using
a CellTiterGlo (CTG) Luminescent Cell Viability
Assay (Promega Co., Madison, WI). Cells were
detached using Trypsin/EDTA and suspended with
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150 μL of CTG solution and incubated for 10 min at
37°C. Luminescent measurements were done on the
plate reader Gemini XP SOK (Molecular Devices).
Lactate dehydrogenase release assay
Cytotoxicity was measured using the index of lactate
dehydrogenase (LDH) release from cells, as described
previously [10]. The LDH activity was measured using
the LDH cytotoxicity assay kit (Nacalai Tesque, Kyoto,
Japan) according to the manufacturer’s instructions.
The culture supernatants of cells transfected with
siRNA were collected at 48 h after the replacement of
media (72 h after siRNA transfection). The collected
supernatants were transferred to another 96-well plate
and incubated with substrate solution at RT for 20 min.
The cells were lysed with cell lysis buffer, then incu-
bated with substrate solution at RT for 20 min. The
stop solution was added and absorbance (490 nm) was
measured. Each absorbance was converted into
a relative value to the control. For normalization, the
relative level of LDH release per cell number was
calculated.
Morphological analysis of EMT
Cellular EMT morphology was analysed as described
previously [8,10]. Briefly, HSC-3-M3 cells were trans-
fected with siRNAs. Then, culture media were replaced
with serum-free ones. Cells were further cultured for
48 h. Then photomicrographs of random four fields
were taken using a Floid® Imaging Station
(ThermoFisher). Spindle-shaped cells were defined as
the cells with more than two-fold length/width ratio.
RT7 cells were cultured in KGM-2 in 96-well plates
and EV (50 μg/mL) or PBS were added to the culture
media. Spindle-shaped cells longer than 80 μm in ran-
dom three fields were counted using ImageJ at 48 h
post-EV addition.
Immunocytochemistry
THP-1 cells were treated with PMA for 24 h for
macrophage-like differentiation. EVs were added to
culture media of the differentiated THP-1 in 96-well
plates at 25 μg/mL. Cells were further cultured for
48 h and fixed with 4% paraformaldehyde in PBS for
10 min and permeabilized with 0.5% Tween-20 in
PBS for 5 min. Immunocytochemistry was carried
out as described previously [5,49]. The fixed cells
were blocked in normal goat serum solution for
30 min, incubated with rabbit anti-CD206 (ab64693,
Abcam) and mouse anti-CD68 IgG (M0814, Dako/
Agilent) in PBS, and incubated with anti-rabbit IgG
AlexaFluor488 and anti-mouse IgG AlexaFluor568.
Cells were incubated with DAPI. Fluorescence images
of random nine fields were taken using Floid®
Imaging Station. To define CD206 or CD68 positiv-
ity, the fluorescence intensity of the cells without the
primary antibody was subtracted as background.
Wound healing assay
Confluent HSC-3 cells in 48-well plates were wounded
by scratching with pipette tips. EVs (50 µg/mL) or PBS
were added to culture media. Images were captured
immediately and subsequently at 8 h using Floid®
Imaging Station. The percentage of the area closed in
8 h was measured using Image J.
Migration assay and invasion assay
Migration/invasion assays were carried out as described
previously [5,51]. Briefly, uncoated and Matrigel-coated
culture systems were used for in vitro migration and
invasion assays, respectively. HSC-3 cells (25 k cells) in
serum-free DMEM were mixed with EVs (10 μg/mL) or
PBS and immediately seeded to an upper chamber of
Transwell® 24-well (Corning). Cells migrated/invaded to
the lower surface of filters were fixed, stained using Diff-
Quick, and counted at 33 h post-seeding period.
Tumoroid formation
Tumoroid (or tumorsphere) formation assay was per-
formed as described [13,45,50,51]. Briefly, HSC-3
cells were cultured with EVs (50 μg/mL) or PBS in
serum-free DMEM in 96-well NanoCulture Plates
(Medical and Biological Laboratories) for 2 days.
Lox-1 probe (Medical and Biological Laboratories)
was added to culture media at 2 μM and then cells/
tumorspheres were cultured for 24 h. Tumorspheres
with red fluorescence were measured using the
ArrayScan HCS System (ThermoFisher). The fluores-
cence intensity was determined using a filter set for
TRITC. For counting spheroids, the size of each
tumorsphere (spheroid) in the entire cell population
was measured. The size of the top 300 tumorspheres
from three wells in each experimental group was
counted and dot-plotted. Fluorescent areas greater
than 300 μm2 were counted in each well and calcu-
lated the average number of spheroids in three wells.
A single well of a 96-well plate was sectionized to 9
fields, and the area of 1 field is 2,632 μm2.
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Patient-derived samples
Sixteen oral squamous cell carcinoma tissues (stage I:
n = 8, stage IV: n = 8) resected at Okayama University
Hospital Oral Surgery were examined. The study was
approved by the Okayama University Human Ethics
Committee (Approval number: 1608–018) and
informed consent was obtained from all patients.
Immunohistochemistry
IHC was carried out as described previously [53,54].
Paraffin blocks of specimens were cut at 3-µm thickness.
The sections were deparaffinized and then autoclaved in
a 0.2% citrate buffer for 15 min. Sections were incubated
with 3% hydrogen peroxide for 30 min. Sections were
treated with 10% normal goat serum for 30min, incubated
with anti-HSP90α (GTX109753, GeneTex) and anti-
HSP90β (GTX101448, GeneTex) antibodies at 4°C over-
night, and visualized with the avidin-biotin complex
method (PK4001, Vector Laboratories). To rate HSP90-
positive cancer cells, five areas were randomly chosen in
each tumour specimen at high magnification (×200) and
HSP90α or HSP90β-positive cancer cells were counted. To
rateHSP90-positive stromal cells, five areas were randomly
chosen in each specimen and HSP90α or HSP90β-positive
stromal cells per 100 mm2 stromal area were counted. The
criteria of positive cells were cells that exhibited DAB
colouration determined by two pathologists.
Co-expression correlation
The data set of head and neck squamous cell carcinoma
(HNSCC) with 523 patient-derived 523 samples (TCGA,
Pan-Cancer Atlas) was analysed using cBioPortal.
Statistical analysis
Statistical significance was calculated using GraphPad
Prism and Microsoft Excel. The difference between the
two sets of data was examined by unpaired student’s
t-test. P < 0.05 was considered to indicate statistical
significance. Data were expressed as means±SD unless
otherwise specified. The size of tumorspheres was sta-
tistically analysed using ANOVA Tukey’s multiple
comparisons test and expressed as mean±SD.
Results
Metastatic oral cancer-derived EVs enriched with
HSP90 promote cancer cell migration
We asked firstly whether HSP90α and HSP90β were
secreted in EVs released by seven oral squamous cell
carcinoma cell lines and one oral epithelial cell line,
known as RT7. HSP90α was found in EVs secreted by
the seven cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2,
HSC-3, HSC-4 and HSC-3-M3) and by RT7 (Fig. S1).
By contrast, HSP90β was markedly found in EVs
secreted by the highly metastatic HSC-3-M3, but
not detected in EVs secreted by the other seven cell
lines. High-metastatic HSC-3-M3-derived EVs (M3-
EV) contained significantly higher levels of HSP90α
and HSP90β compared to HSC-3-derived EVs
(HSC3-EV) (Figure 1a,b; Fig. S2). Additionally, M3-
EV contained a higher level of CD326 compared to
HSC3-EV. Moreover, M3-EV tended to contain
a higher level of CD63 compared to HSC3-EV. Both
HSC3-EV and M3-EV possessed cup-like shapes
(Figure 1c, Fig. S3), although M3-EV (average
141.8 nm) tended to be larger than HSC3-EV (aver-
age 119.2 nm) (Figure 1d–g; Fig. S4). The main
populations of HSC3-EV and M3-EV were between
50 and 200 nm diameters.
We next examined the co-expression correlation
between the HSP90AA1 gene, which encodes HSP90α
and the HSP90AB1 gene encoding HSP90β, among 523
tumour samples derived from 523 HNSCC patients
registered in the cancer genome atlas. A high-level co-
expression correlation was found between HSP90AA1
and HSP90AB1 with Spearman’s correlation score 0.52
(p = 2.59e−37), Pearson’s correlation score 0.50
(p = 2.71e−34) and a regression line (y = 0.44x±8.39)
(Figure 1h). The positive correlation of co-expression
between HSP90AA1 and HSP90AB1 may be consistent
with the co-expression of HSP90α and HSP90β observed
in M3-EV derived from high-metastatic oral cancer in
Figure 1a,b. To query the pro-migratory potential of oral
cancer-derived HSC3-EV and M3-EV, we next per-
formed a scratch wound-healing assay. Treatment with
either M3-EV or HSC3-EV promoted significant levels
of migration of HSC-3 cells, effectively closing the
scratched wound, while M3-EV was a more potent pro-
migratory agent than HSC3-EV (Figure 1i,j).
These data indicate that metastatic oral cancer-
derived EVs are enriched with HSP90α and HSP90β
and promote cancer cell migration.
siRNA-mediated knockdown of CDC37/HSP90α/
HSP90β diminishes the EMT phenotype in
metastatic oral cancer cells
We have shown that M3-EV tended to be enriched
with HSP90α and HSP90β [12]. We also reported that
the double-knockdown of HSP90α and HSP90β signif-
icantly reduced the survival of metastatic oral cancer
cells, although single knockdown of each HSP90 was
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ineffective in this regard [12]. Next, we examined
whether the knockdown of CDC37/HSP90α/β could
alter the survival of metastatic oral cancer cells. Single
knockdown of each chaperone did not alter the survi-
val of HSC-3-M3 cells, while the triple knockdown of
CDC37/HSP90α/β reduced the survival of the
metastatic oral cancer cells (Fig. S5). It was thus sug-
gested that triple targeting of the molecular chaperone
trio could be antitumorigenic and potentially damage
targeted cells.
Increases in cellular migration and motility have
been associated with a phenotypic change of the cells
Figure 1. Different characters of high- and low-metastatic oral cancer-derived EVs. (a) Western blotting showing HSP90α, HSP90β,
tetraspanins (CD9, CD63), and CD326 in HSC-3-derived EVs (HSC3-EV) and HSC-3-M3-derived EVs (M3-EV). Similar data were
obtained from three independent experiments. (b) Column scatters plotting to compare protein levels in HSC3-EV vs. M3-EV.
Relative band intensities of Western blotting were plotted. (c) Representative TEM images of HSC3-EV and M3-EV. Scale bars,
100 nm. (d,e) Representative particle diameter distribution of (d) HSC3-EV and (e) M3-EV. (f) EV size peaks from five independent
experiments. Dotted lines indicate the same sets of experiments. (g) The ratio of EV size peaks. (h) Scatter plot showing co-
expression correlation between HSP90AA1 and HSP90AB1 in HNSCC. A regression line was shown in red. Data were represented as
log2. The data set of head and neck squamous cell carcinoma (HNSCC) with 523 patient-derived 523 samples (TCGA, Pan-Cancer
Atlas) was analysed using cBioPortal. (i,j) Wound healing assay of HSC-3 cells treated with PBS, HSC3-EV or M3-EV. (i) Representative
images at 8 h after the wounding. — (blue) initial wounds. — (red) closed wounds at 8 h. Scale bars, 200 μm. (j) Rate of the wound
closure. n = 4.
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from epithelial to mesenchymal properties – EMT [26].
CDC37, a key cochaperone for both paralogs of HSP90,
is essential in chaperoning the EMT-promoting kinase
signals in cancer cells [28,44]. Moreover, knockdown of
CDC37 diminished EV protein release and the EMT
properties of prostate cancer cells [10,55]. We therefore
next asked whether CDC37 and HSP90α/β could act
cooperatively in the EMT process. This experiment
involved targeting of CDC37, HSP90α and/or HSP90β
and determining the levels of EMT markers in HSC-
3-M3. We first confirmed that individual siRNA aimed
at either HSP90α, HSP90β or CDC37 could successfully
silence the translated protein levels of their mRNA
targets in HSC-3-M3 (Figure 2a, top to third raw
blot; Fig. S6). However, siRNA-mediated depletion of
HSP90α triggered simultaneous increases in HSP90β,
while depletion of HSP90β triggered simultaneous
increases in HSP90α as well, suggesting
a compensatory response within the CDC37/HSP90
system. This observed compensatory response there-
fore rationalized the use of double and triple depletion
of CDC37, HSP90α and HSP90β in this study to effec-
tively neutralize the HSP90/CDC37 chaperone system.
Additionally, the siRNA-mediated silencing of HSP90β
reduced the level of CDC37, and vice versa, the silen-
cing of CDC37 led to reductions in both CDC37 and
HSP90β. Nevertheless, double and triple targeting of
CDC37, HSP90α and/or HSP90β successfully dimin-
ished the levels of each of the chaperone trio in the
metastatic oral cancer cells (Figure 2a, top to third raw
blot; Fig. S6).
Next, we asked whether EMT properties could be
altered by the chaperone depletion. The concentration
of the most prominent mesenchymal marker vimentin
was reduced by either a combination of double deple-
tion or most profoundly by the triple knockdown of
the chaperone trio (Figure 2a–c, Fig. S7). The epithelial
marker E-cadherin was increased by double depletion
of HSP90α/β and by triple chaperone depletion
(Figure 2a–c). The most prominent alteration was
observed in the levels of claudin-1, an epithelial tight
junction component. Claudin-1 was profoundly ele-
vated by either single depletion of CDC37 alone or
double/triple depletion of CDC37/HSP90α/β
(Figure 2a–c), suggesting that silencing CDC37 could
lead to the claudin-1-positive epithelial phenotype.
Figure 2. The siRNA-mediated knockdown of CDC37/HSP90α/HSP90β diminishes the EMT phenotype in metastatic oral cancer cells.
(a) Representative Western blotting showing HSP90α, HSP90β, CDC37, and EMT markers. HSC-3-M3 cells were transfected with
siRNAs targeting CDC37, HSP90α and/or HSP90β or non-targeting siRNA (si-Ctrl) for 48 h. COX4, loading control. Similar data were
obtained from two independent experiments. (b–e) Anti-EMT effect of triple chaperone knockdown. HSC-3-M3 cells were
transfected with siRNAs targeting CDC37/HSP90α/HSP90β or si-Ctrl. Medium was replaced with serum-free one at 24 h post-
transfection. Cells were further cultured 48 h prior to protein sampling and photo taking. (b) Western blotting showing EMT
markers. β-actin, loading control. Similar data were obtained from four independent experiments. (c) Alteration of EMT markers. The
band intensities of Western blotting were quantified. (d,e) Morphological analysis of EMT. (d) Representative photomicrographs of
HSC-3-M3 cells transfected with siRNA. Arrowheads indicate spindle-shaped cells. Scale bars, 100 μm. Similar data were obtained
from three independent experiments. (e) Rates of spindle-shaped cells. Spindle shaped cells were defined as the cells with more
than two-fold length/width ratio. n = 4 random fields.
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CD326 aka EpCAM has been shown as a type of
epithelial marker as well as tumour-initiating cell mar-
ker [13,56,57]. In our study, CD326 tended to be
increased by the triple knockdown of the chaperones,
consistently with other epithelial markers (Figure 2b,c).
Thus, triple depletion of CDC37/HSP90α/β reduced
the EMT properties of metastatic oral cancer cells
more effectively than both single and double chaperone
depletion.
We next examined morphological changes in the
metastatic oral cancer cells upon chaperone silencing.
To evaluate morphological changes coupled with EV
release, the culture medium was replaced with serum-
free one at 24 h post-transfection and cells were further
cultured for 48 h before photo taking and EV sampling.
Cell viabilities were not much altered in this protocol
between the control and triple knockdown (Fig. S8).
The most noticeable difference was observed between
control siRNA-transfected and triple-silenced cells.
A spindle-like shaped morphology, one of the principal
characteristics of EMT, was observed in the control
cells, whereas cells significantly reverted to a more
typically epithelial morphology upon triple chaperone
depletion (Figure 2d,e; Fig. S8).
These findings indicate that the siRNA-mediated
triple chaperone knockdown of CDC37, HSP90α and
HSP90β could diminish the EMT phenotype in meta-
static oral cancer cells.
Triple chaperone knockdown reduced HSP90α,
HSP90β and tetraspanins in metastatic EVs
It has been shown that tetraspanins such as CD9 and
CD63 play crucial roles in intercellular communication
[58–60]. Besides, we recently reported that a single
knockdown of CDC37 reduced EV-associated CD9
release from prostate cancer cells [10]. We therefore
hypothesized that molecular chaperones could regulate
the stability and release of tetraspanins with EVs. We
queried whether siRNA-mediated triple depletion of
CDC37/HSP90α/β could alter the incorporation of
HSP90 and tetraspanins (CD9 and CD63) from cancer
cells to EVs. We here used the same protocol of cell
culture used in Figure 2d,e and Fig. S8. We observed
depletion of HSP90α levels in cell lysates, EV fractions
and the EV-free soluble culture supernatant by the
triple chaperone depletion (si-Ctrl vs si-CDC37
/HSP90α/β) (Figure 3a–c, Fig. S9).
We recently reported that cell stress triggered stres-
some release including extracellular HSP90α and
damaged membrane vesicles [10]. It is conceivable
that siRNA transfection could also lead to membrane
damage and the release of cytosolic proteins and intra-
EV cargos. The release of EV-free HSP90α was inhib-
ited by the triple knockdown, while extracellular β-
actin was increased in the soluble fraction of the triple
chaperone knockdown compared to the control
(Fig. S9).
The depletion of HSP90β was also confirmed in the
cellular and EV fractions by the triple chaperone target-
ing, although HSP90β was not found in the EV-free
culture supernatant (Figure 3a–c, Fig. S9). These data
were consistent with previous reports showing that
tumour-derived EVs could often carry HSP90α and
HSP90β as cargo [10,12] while secretion of EV-free extra-
cellular HSP90α was also observed [10,13,61].
CDC37 was reduced in metastatic oral cancer cells by
triple chaperone silencing, although this chaperone was
not found in the extracellular fractions, consistent with
our recent report [10]. Notably, tetraspanins CD9 and
CD63 were reduced by the triple chaperone silencing in
metastatic oral cancer-derived EVs (Figure 3a–c).
These data indicated that CDC37/HSP90 might play
a crucial role in the stability and vesicular incorpora-
tion of tetraspanins CD9 and CD63.
As CDC37 and HSP90 have been shown to regulate
proteostasis [10,30], we next examined whether protein
levels in HSC-3-M3 cells and their EVs were altered by
triple chaperone depletion compared to the control.
Indeed, triple chaperone depletion significantly
reduced overall protein levels in the cells, although
not altering the EV protein level (Figure 3d,e). These
data suggest that reduction in CDC37/HSP90 may
increase cellular proteolysis of unfolded proteins in
the cytoplasm, although effects on protein synthesis
and maturation may also be involved.
Hereafter, we define EVs derived from control
siRNA-transfected HSC-3-M3 cells as MEV, and EVs
derived from triple siRNA (CDC37/HSP90α/β) trans-
fected HSC-3-M3 cells as T-MEV. Next, we compare
the different properties of MEV and T-MEV. The
morphologies and sizes of EVs were similar between
MEVs and T-MEVs. MEVs and T-MEVs had cup-like
morphologies (Figure 3f,g; Fig. S10). The main popula-
tions of MEV and T-MEV sized between 50 and
400 nm with a peak at approx. 185 nm, while minor
smaller particles (20–30 nm) were detected (Figure 3h,
i; Fig. S10).
These data suggest that the chaperone trio CDC37/
HSP90α/β could be crucial in intracellular proteostasis
and extracellular release of EV proteins, including tet-
raspanins and thereby triple chaperone knockdown
altered proteome signature including CD9 and CD63
in the cells and EVs.
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Triple chaperone knockdown reduced Gluc-EV
release
We recently showed that cell stress triggers the release
of stressome including EVs, HSP90 and LDH, a marker
of cell membrane damage, from cancer cells [10].
CDC37 was also induced intracellularly by cell stress
[10]. We therefore hypothesize that the chaperone trio
is involved in membrane damage-related release
of EVs.
Moreover, a previous study reported that Gaussia
princeps-derived luciferase (Gluc) fused with PDGFR
transmembrane domain was anchored to the lipid-
bilayered membrane and then released from producer
cells [48]. To quantify the release of EVs, we
established a stable cell line designated as
HSC3 M3/mbGluc that produce membrane-bound
Gluc (mbGluc) (Figure 4a,b). The morphology of
vesicles released by the HSC3 M3/mbGluc cells was
cup-shaped and sized between 50 and 200 nm (Figure
4c, Fig. S11). Gluc activity was detectable and quan-
titative in the culture supernatant of HSCM3/mbGluc
cells (Figure 4d,e). mbGluc was released from HSC-
3-M3/mbGluc cells into culture media in a time-
dependent manner at 6, 24 and 48 h culture period
(Figure 4f). Triple targeting of CDC37/HSP90α/β
lowered the release of mbGluc at 6–24 h post-
medium replacement (Figure 4f). These data indicate
that the chaperone trio is involved in EV release.
Figure 3. Triple knockdown of CDC37/HSP90α/HSP90β inhibits proteostasis and alters properties of EVs. HSC-3-M3 cells were
transfected with non-targeting siRNA (si-Ctrl) or siRNA mixture targeting CDC37, HSP90α, and HSP90β (si-CDC37/90α/β). Medium
was replaced with serum-free one at 24 h post-transfection. Cell lysates, EV and non-EV soluble fractions of culture supernatants
were collected at 48 h post-medium change. (a) Representative Western blotting showing HSP90, CDC37, CD9, CD63 and β-actin. (b,
c) Column scatters plotting to compare protein levels between si-Ctrl vs. si-CDC37/90α/β groups in cells (b) and EVs (c). Relative
band intensities of Western blotting were plotted. (d,e) Protein quantification of the whole cell lysates and EV fractions. (d) Total
cellular protein levels per 106 cells. n = 3. (e) Total EV protein levels per 106 cells. n = 3. (f,g) Representative TEM images of EV
fractions at (f) high and (g) low magnifications. Scale bars, 200 nm. (h,i) Particle diameter distribution of EV fractions from HSC-3-M3
transfected with si-Ctrl (h) or si-CDC37/90α/β (i), called MEV and T-MEV, respectively.
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The total protein concentrations of the EV fractions
were not different between the triple knockdown ver-
sus the control, as shown in Figure 3e. However,
mbGluc release was delayed by the triple knockdown.
Therefore, it is conceivable that EVs containing
mbGluc, HSP90, CD9 and CD63 were reduced by the
triple knockdown, while other components must be
increased instead.
We also examined whether cellular growth, viability,
and damage were altered by the triple knockdown of
CDC37/HSP90α/β in HSC3 M3/mbGluc cells. Cellular
growth and viability were not altered between the triple
siRNA-transfected cells and control cells (Fig. S12a–d),
while LDH release was inhibited by the triple knock-
down of CDC37/HSP90α/β (Fig. S12e–g).
These data indicated that triple knockdown of
CDC37/HSP90α/β could lower the release of EVs
from cancer cells.
Triple depletion of CDC37/HSP90α/HSP90β
attenuated cancer EV-driven malignancy events
We next examined the effects of MEV and T-MEV on
properties associated with processes involved in
malignant progression, including the initiation of
EMT in normal epithelial cells, advanced migration,
invasion and tumorigenesis of oral cancer cells. MEV
treatment of epithelial RT7 cells significantly
increased the number of spindle-shaped cells com-
pared to the PBS-treated control, whereas the EMT-
initiating properties of MEV were significantly
reduced by triple chaperone depletion (Figure 5a,b;
Fig. S13). To confirm the alteration of EMT at the
level of protein markers, we performed western blot
analysis. Claudin-1 and E-cadherin were markedly
reduced by MEV treatment of the epithelial cells
compared to the PBS-treatment control, whereas tri-
ple chaperone depletion prevented the reduction in
Figure 4. Triple knockdown of CDC37/HSP90α/β inhibited the release of membrane-bound Gaussia luciferase (mbGluc) reporter.
The expression construct of mbGluc fused with the PDGFR transmembrane domain was stably transfected to HSC-3-M3 cells. GFP
was co-expressed by an internal ribosomal entry sequence (IRES) for labelling the donor cells designated as HSC3M3/mbGluc. (a)
Schemes showing a concept of Gluc-labelled EVs. (b) Representative images of HSC3M3/mbGluc cells. Left, an image of GFP-
expressed HSC3M3/mbGluc cells. Right, a bright-field image. Scale bars, 100 μm. (c) A representative TEM images of mbGluc-MEV.
Scale bars, 200 nm. (d, e) Establishment of mbGluc quantification. (d) Relative Gluc activities of 20 μL culture media of HSC-3 (as
negative control) and HSC3M3/mbGluc cells. (e) A standard curve of Gluc activities. Culture media were prepared at 48 h after the
medium change. (f) Relative Gluc activities of MEV and T-MEV. HSC3M3/mbGluc cells were transfected with control siRNA or si-
CDC37/HSP90α/β for 24 h and then culture media were replaced with fresh ones. Gluc activities in the culture supernatants were
measured at 6, 24 and 48 h after the medium changes. Values were normalized with the number of cells. n = 3.
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claudin-1 and E-cadherin (Figure 5c; top and second
raw blot; Fig. S14). Consistent with the reduced
epithelial properties, a representative mesenchymal
marker protein, vimentin was increased by the MEV
treatment (Figure 5c; third raw blot). Meanwhile,
Snail, a protein whose stability is important for the
establishment of the EMT phenotype was increased
by the MEV treatment, although also increased by
T-MEV treatment (Figure 5c; fourth raw blot). β-
catenin, whose activity is also important in the induc-
tion of EMT, was also increased by the MEV treat-
ment of the epithelial cells (Figure 5c; bottom second
blot). Triple chaperone depletion inhibited MEV-
triggered increases in vimentin and β-catenin.
Therefore, these data indicate that: (i) metastatic
oral cancer-derived MEV was a potent inducer of
EMT in epithelial cells and (ii) triple chaperone
depletion effectively reduced EMT-initiating activity
of metastatic EVs.
We next hypothesized that the EMT-inducing activ-
ity of MEV could potentially lead to augmented migra-
tion, invasion, and tumorigenesis of oral cancer cells.
MEV promoted migration of HSC-3 cells as demon-
strated by the scratch wound healing assay and by the
chamber-well migration assay (Figure 5d–i). The deple-
tion of the chaperone trio inhibited the MEV-driven
migration of oral cancer cells (Figure 5d–g, MEV vs.
T-MEV). MEV also promoted oral cancer cells to
invade through matrices, whereas triple chaperone
depletion attenuated the MEV-driven invasion (Figure
5h,i).
These data indicate that MEV initiates EMT in oral
epithelial cells, an event attenuated by triple chaperone
depletion. Additionally, MEV enhanced migration and
invasion of oral cancer cells, events inhibited by triple
chaperone depletion.
Triple depletion of CDC37/HSP90α/HSP90β
attenuated cancer EV-driven tumorsphere
formation
We have originally developed a 3D culture system for
the evaluation of in vitro tumorigenesis with enhanced
expression of cell adhesion molecules such as
E-cadherin and CD326/EpCAM and cancer stem cell
markers [13]. Next, we determined whether MEV
could promote in vitro tumorigenesis and asked if
depletion of the chaperone trio could cancel the MEV-
driven tumorsphere formation. As TGFβ pro-
migratory activity can promote intercellular attach-
ment leading to sphere formation [62], we used TGFβ-
Figure 5. Triple depletion of CDC37/HSP90α/HSP90β inhibited EV-driven malignancy events. (a-c) EMT levels altered by MEV and
T-MEV. Epithelial cell line RT7 was treated with MEV, T-MEV or PBS. (a) Rate of spindle-shaped cells longer than 80 μm. n = 3. (b)
Representative images of RT7 cells. Scale bars, 100 μm. (c) Western blotting showing EMT markers. (d,e) Wound healing assay. HSC-
3 cells were treated with MEV, T-MEV or PBS. (d) Rate of wound closure. n = 12. (e) Representative photomicrographs of closing
wounds. — (blue) initial wounds. — (red) closed wounds at 8 h. Scale bars, 200 μm. (f,g) Migration assay using a transwell system.
(f) Migration activities of HSC-3 cells treated with MEV, T-MEV or PBS. n = 3. (g) Representative images of migrated cells. Cells were
stained with Diff-Quik. Scale bars, 1 mm. (h,i) Invasion assay using Transwell system. (h) Invasion activities of HSC-3 cells treated
with MEV, T-MEV or PBS. n = 3. (i) Representative images of invaded cells. Cells were stained with Diff-Quik. Scale bars, 1 mm.
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promoting tumorsphere formation as a positive con-
trol. Tumorsphere formation by HSC-3 cells was sig-
nificantly enhanced by MEV treatment (50 μg/mL) and
by TGFβ treatment (5 ng/mL) compared to the PBS-
treated control (Figure 6a,b; Fig. S15). Triple chaperone
depletion significantly lowered the tumorsphere form-
ing potential of MEV (Figure 6a,b; MEV vs. T-MEV).
Moreover, T-MEV significantly inhibited tumorsphere
formation compared to the control. The number of
tumorspheres was significantly less in the T-MEV
group than that in the MEV group (Figure 6c).
Some aspects of tumorigenesis, as well as tumor-
sphere formation, may require intercellular adhesion
by CD326/EpCAM and E-cadherin and tight junc-
tions formed by claudins [13,63,64]. Moreover, MEV
tended to be enriched with CD326, as indicated in
Figure 1. We therefore next asked whether the addi-
tion of MEV, T-MEV or TGFβ could alter CD326,
E-cadherin, β-catenin and claudin-1 in tumorspheres.
The addition of MEV or TGFβ stimulation increased
levels of CD326, E-cadherin, β-catenin and claudin-1
in tumorspheres, while T-MEV tended to show lesser
effects (Figure 6d, Fig. S16). Consistently, co-
expression correlation of CD326/EpCAM and tetra-
spanin CD9 was found in HNSCC clinical cases with
Spearman’s correlation score 0.51 (p = 1.43e−33),
Pearson’s correlation score 0.50 (p = 1.49e−32), and
a regression line (y = 0.99x±3.91) (Figure 6e), suggest-
ing that CD326/EpCAM-related tumour-initiating
activity could be involved in tetraspanins-bearing EV
transmission.
These findings indicate that metastatic oral cancer-
derived EVs increase cancer malignancy by promoting
EMT, migration, invasion and tumorigenesis of oral
cancer cells, whereas the siRNA-mediated triple deple-
tion of CDC37/HSP90α/β could inhibit the MEV-
driven oral cancer malignancy progression.
HSP90α is dominantly expressed in cancer cells,
while HSP90β is accumulated in tumour-associated
macrophages in metastatic oral cancer
To examine the expression and tissue localization
of HSP90α and HSP90β in the tumour microenvir-
onment, we next performed immunohistochemistry
(IHC) on tumour specimens derived from patients
Figure 6. Metastatic EVs promote tumorsphere formation, a property diminished by triple chaperone knockdown. (a–d) In vitro
tumorigenesis assay in the three-dimensional (3D) culture system. HSC-3 cells were treated with MEX (50 μg/mL), T-MEX (50 μg/mL),
TGFβ (5 ng/mL) or PBS in nano-culture plates and then (a–c) tumorsphere formation and (d) protein expression levels were
examined. (a) Representative photomicrographs of tumorspheres. Scale bars, 100 μm. (b) Column scatter plotting showing
tumorsphere size. The size of the top 300 tumorspheres was measured in each group using ArrayScan HCS System. The horizontal
lines indicate mean ± SD analysed by ANOVA Turkey’s multiple comparisons test. (c) The number of tumorspheres altered by MEX
or T-MEX. Tumorspheres larger than 200 mm2 were counted. n = 3, P = 0.0201. (d) Western blotting showing CD326/EpCAM,
E-cadherin, β-catenin, claudin-1 and β-actin. The cell lysates were prepared from the tumorspheres. (e) Scatter plot showing co-
expression correlation between CD326/EpCAM and CD9 in head and neck squamous cell carcinoma (HNSCC). A regression line was
shown in red. Data were represented as log2. The data set of HNSCC with 523 patient-derived 523 samples (TCGA, Pan-Cancer Atlas)
was analysed.
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suffering from stage IV (with metastasis) vs. stage
I (without metastasis) oral squamous cell carci-
noma. The HSP90α-positive cancer cell rate in the
stage IV group was significantly higher than that in
stage I (Figure 7a,b; Fig. S17). HSP90α-positive
cells were also found in the stroma, although the
levels were not significantly different between stage
I and stage IV (Figure 7c). In contrast, the
HSP90β-positive cancer cell rate in the stage
I group was significantly higher than that in stage
IV (Figure 7a,d). However, the HSP90β-positive
stromal cell rate in stage IV oral cancer group
was significantly higher than that in stage
I (Figure 7a,e; Fig. S17). Additionally, we found
that HSP90β-positive round-shaped cells and den-
dritic cells were infiltrating into tumours in stage
IV oral cancer and were morphologically reminis-
cent of macrophages (Figure 7f, arrowheads).
These data suggested that HSP90 abundantly
released by cancer cells could be taken TAM.
Figure 7. Metastatic oral cancer-derived MEVs induced macrophages M2 polarization. (a–f) Immunohistochemistry (IHC) of oral
cancer patient-derived specimens. (a) Representative IHC showing HSP90α and HSP90β in stage I vs. stage IV oral cancers. Tu,
tumour. St, stroma. — borders between tumour and stroma. (b–e) Rate of (b,c) HSP90α+ or (d,e) HSP90β+ cancer cells or stromal
cells. The rates were calculated by counting immuno-positive cells per total cell number in each random field in (b,d) tumour areas
or (c,e) 100 mm2 stromal areas. Five random fields each in 8 oral cancer cases. N = 40. (f) IHC for HSP90β in stage I vs. stage IV oral
cancer. Arrowheads, HSP90β-positive infiltrating tumour-associated macrophages (TAM). (g–j) Macrophage M2 polarity was altered
by MEV and T-MEV. THP-1 cells were stimulated with PMA for the differentiation to macrophages and then treated with MEV, T-MEV
(25 μg/mL) or PBS. (g) Representative images of THP-1 cells treated with or without PMA for 24 h. (h) Western blotting of
extracellular and intracellular MMP-9 in THP-1 cells with or without PMA treatment. (i,j) Immunocytochemistry of macrophage
markers with or without MEV or T-MEV. (i) Rate of CD206/CD68 double-positive M2-like macrophages. N = 9. (j) Representative
staining images of CD206 (green) and CD68 (red). Blue, DAPI. Scale bars, 100 μm.
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Metastatic EVs induce macrophages M2
polarization
Next, we asked whether macrophage M2 polarization
could be altered by metastatic oral cancer-derived
MEVs. As it has been shown that pro-tumorigenic
metalloproteinase MMP9 was produced by M2
macrophages [65], we queried whether PMA and
MEV could alter the MMP9 levels and release by
macrophages. The monocytic cell line THP-1 was
first differentiated to macrophage-like cells by stimu-
lation with the phorbol ester PMA before EV treat-
ment. THP-1 cells were morphologically monocytic
and non-adherent to tissue culture plates without
PMA stimulation while the differentiated macro-
phage-like THP-1 cells adhered to tissue culture plates
after the PMA treatment (Figure 7g, Fig. S18).
Moreover, MMP9 was detectable in the PMA-treated
THP-1, although not detectable without PMA treat-
ment (Figure 7h). MMP9 secretion by THP-1-derived
macrophages was enhanced by the MEV treatment,
compared to PBS-treated control cells. Triple chaper-
one targeting of HSC-3-M3 reduced the MEV-driven
MMP9 production by the macrophage-like cells (Fig.
S19). The treatment with MEV tended to increase
HSP90β in the macrophage-like cells, while T-MEX
treatment showed a lesser effect.
To query whether the exposure to MEV could alter
macrophage polarity, we next examined the expression
of CD206, an M2 polarity marker, and CD68, a general
macrophage marker. CD206/CD68 double-positive
macrophages were significantly increased by the MEV
treatment compared to PBS-treated control cells
(Figure 7i,j; Fig. S20). Triple depletion of CDC37/
HSP90α/β in HSC-3-M3 reduced the MEV-driven
macrophage M2 polarization (Figure 7i,j; MEV vs.
T-MEV).
These data show that metastatic oral cancer-derived
EVs induce macrophage M2 polarization, a phenotype
inhibited by triple depletion of CDC37/HSP90α/HSP90β.
In addition, MEV-derived HSP90β could accumulate in
macrophages and was involved in the M2 polarization.
Triple depletion of CDC37/HSP90α/HSP90β lowered
EV transmission potentials
Next, we compared the transmission potentials of MEV
and T-MEV to recipient cells. We have established and
tested two methods of the EV labelling: (i) labelling EVs
with red-fluorescent sphingolipid [8,45] and (ii) estab-
lishment of stable cells that produced membrane-bound
palmitoylation signal-linked GFP or tdTomato red-
fluorescent proteins [46]. Using the first method, we
found that the transmission potential of T-MEV was
significantly lower than that of MEV at 1.5 and 3 h after
the EV addition to HSC-3 cells, although it was not
significant at 6 and 12 h, indicating that there was a time-
dependent reduction of the rate of transmission of EVs
(Figure 8a,b).
A previous study had reported that GFP, as well as
tdTomato RFP, fused with protein palmitoylation signal
(designated palmtdTomato and palmGFP, respectively),
were associated with the EV membrane, thus being
released from producer cells into the culture supernatant
[46,47]. To monitor the transmission of EVs, we estab-
lished palmtdTomato-expressed HSC-3-M3 cells (desig-
nated HSC3M3/palmT), palmGFP-expressed HSC-3-M3
cells (designated HSC3M3/palmG), palmGFP-expressed
HSC-3 cells (designated HSC3/palmG) and palmGFP-
expressed THP-1 cells (designated THP1/palmG)
(Figure 8c,d; Fig. S21). We collected EVs (palmT-
MEV) from the culture supernatant of HSC3M3/
palmT cells (Figure 8e). We then confirmed that the
palmT-MEV were produced from HSC3M3/palmT cells
and then being transmissive into HSC3M3/palmG cells,
under CLSM (Figure 8f; Fig. S22a,b). Dose-dependent
transmission of EVs was found in palmT-labelled MEV
and T-MEV (Figure 8g). Triple targeting of CDC37/
HSP90α/β significantly lowered the transmission of the
palmT-labelled MEV into the recipient HSC3/palmG
cells at 1, 3, and 6 h after the addition of the EVs
(MEV vs. T-MEV) (Figure 8g,h; Fig. S22 c). To monitor
the transmission of palmT-MEV into macrophages,
THP1/palmG cells were differentiated into macrophage-
like cells with PMA. Triple targeting of CDC37/HSP90α/
β significantly lowered the uptake of the palmT-MEV by
macrophages (Figure 8i,j; Fig. S22d). T-MEV uptake by
macrophages was significantly lower than MEV and this
lasted at least 24 h after the addition of EVs (Fig. S22e).
Thus, triple depletion of CDC37/HSP90α/HSP90β
in metastatic oral cancer cells inhibited cancer vesicular
transmission to recipient cells such as macrophages.
Discussion
Our data indicate the potency of metastatic tumour-
derived EVs in changing the tumour microenvironment
into a more pro-malignant state. We demonstrate that oral
cancer-derived EVs possess the potential to initiate epithe-
lial cell transformation – EMT, to promote the tumori-
genic, migratory and invasive abilities of oral cancer cells
and to polarize macrophages into an M2 phenotype. To
potentially target these pro-malignant events, our data, for
the first time, indicate the validity of triple depletion of the
interacting CDC37/HSP90α/HSP90β complex (Figure 9,
graphical abstract). siRNA-mediated triple depletion of
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CDC37/HSP90α/β significantly diminished the pro-
malignant activities of oral cancer cells and MEVs.
Although earlier studies had shown that intracellular
HSP90 promotes cancer progression, indicating its target-
ing by small molecule inhibitors in clinical trials, we have
uncovered novel roles for the co-chaperone CDC37 in
cancer [10,14,28–30,44,55]. Notably, our data indicate
that individual depletion of either HSP90α, HSP90β or
CDC37 triggers simultaneous increases in the other cha-
perones. This observed compensatory response within the
CDC37/HSP90 system was the rationale behind our origi-
nal approach of depleting the three chaperones. Indeed,
our data indicated that cancer-initiation and EMTmarkers
were attenuated by the triple chaperone depletion more
profoundly than double depletion. Consistently, our recent
study showed that triple depletion of the chaperone trio
inhibited tumorigenesis of prostate cancer cells in vivo [10].
As a potential mechanism, a recent study showed that
directional cell movement through tissues is controlled by
EV secretion [11,66]. Consistently, our data indicate that
HSP90-high oral cancer-EVs promote migration-
dependent tumorigenesis of cancer cells; triple chaperone
depletion significantly diminished the pro-migratory activ-
ities of EVs. Thus, our studies could offer a potential solu-
tion to the pro-migratory and pro-tumorigenic activities of
cancer EVs.
Figure 8. Triple knockdown of CDC37/HSP90α/HSP90β attenuates EV transmission potential into recipient macrophages and cancer
cells. (a,b) Transmission of MEV and T-MEV into recipient HSC-3 cells. MEV was prepared from the culture supernatant of HSC-3-M3
transfected with si-Ctrl. T-MEV was prepared from the culture supernatant of HSC-3-M3 transfected with si-CDC37/90α/β. MEV and
T-MEV were labelled with red-fluorescent ceramide and added to the culture media of HSC-3 cells. Cells were fixed at the indicated
incubation period and analysed under fluorescent microscopy. (a) Representative images of vesicular transmission. Scale bars,
50 μm. Blue, DAPI staining. (b) The rate of EV transmission per total cells. N = 3. (c-j) Monitoring EVs labelled with membrane-bound
palmitoylation (palm) signal-fused fluorescent proteins. (c) A scheme of the concept of fluorescent EV transmission. (d)
Representative fluorescent images of HSC3M3/palmT, HSC3M3/palmG, HSC3/palmG and THP1/palmG cells. THP1/palmG was
stimulated with PMA. Scale bars, 100 μm. (e) Representative TEM images of MEV released by HSC3M3/palmT cells. Scale bars,
200 nm. (f) Confocal laser scanning microscopy of HSC3/palmG cells treated with or without palmT-MEV. MEV (red) were prepared
from culture media of HSC3 M3/palmT cells and added to the culture media of HSC3/palmG cells (green). Blue, DAPI staining. Scale
bars, 20 μm. (g–j) MEV transmission rate into (g,h) HSC3/palmG cells or (i,j) THP1/palmG macrophages. For macrophage
differentiation, THP1/palmG cells were stimulated with PMA. (g,i) Column scatters plotting of MEV transmission. The values indicate
palmT fluorescence intensity per cell at 1 h after the addition of MEV or T-MEV. The upper end of each column indicates mean. (h,j)
Transmission efficiencies of MEV vs. T-MEV into (h) HSC3/palmG cells and (j) THP1/palmG-derived macrophages. n = 3.
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Our studies also, for the first time, indicate a potent
role of HSP90-rich EVs in trans-cellular communica-
tion in the tumour microenvironment. It has been
shown that cancer cell-derived EVs induce macrophage
M2 polarity in breast cancer [67], colon cancer [37],
pancreatic cancer [38], ovarian cancer [68], brain can-
cer [69], and head and neck cancer [42]. It was also
reported that TAM showed an M2-type polarity in oral
cancer and the number of such infiltrating TAM was
correlated with poor prognosis [70]. Our studies were
consistent with these reports, although, in oral cancer
patient-derived tumours, we found that HSP90β-
positive TAMs were profoundly associated with and
infiltrating into the tumours. Distinctively, HSP90α
might be processed during phagocytosis and antigen
presentation, as HSPs play key roles in capturing
tumour antigens and permitting their uptake and pro-
cessing by antigen-presenting cells prior to activation
of cytotoxic lymphocytes [17,71–74]. Relevantly, it has
been shown that complexes of antigenic peptides with
HSP90, calreticulin, and HSP70 were taken up by
macrophages and dendritic cells and re-presented by
MHC class I molecules [73,75]. Importantly, HSP90
mediates efficient antigen cross-presentation through
scavenger receptors such as SCARF1 and LOX-1
[76,77]. Moreover, circulating EVs containing HSP90
were demonstrated to mediate the activation of macro-
phages and Kupper cells in alcoholic liver disease [78].
Our current study indicated that loss of HSP90α/β
significantly inhibited EV uptake by macrophages.
Thus, it is conceivable that HSP90 is crucial for EV
uptake, activation and M2-type polarization of macro-
phages. Our findings support one of our conclusions,
namely that metastatic oral cancer releases HSP90-rich
EVs leading to polarization of macrophages to an M2
phenotype, while triple chaperone knockdown is effec-
tive in inhibiting EV uptake by TAM and their M2
polarization.
Our studies also suggest that tetraspanins (CD9 and
CD63) might be crucial mediators for cell-cell commu-
nication in tumour progression and programming of
the microenvironment. It has been shown that tetra-
spanins are crucial for intercellular communications
required for cancer progression [64,79,80], while CD9
and CD63 are exosome markers and potentially con-
tained in other EV types [1]. In our study, the total
protein concentrations of the EV fractions were not
different between the triple knockdown versus the con-
trol, while EVs that contained HSP90, CD9, CD63 and
mbGluc appeared to be reduced by the triple
Figure 9. Graphical abstract. (a) Metastatic oral cancer cells secreted HSP90-high EVs transmitting to recipient cells. Metastatic oral
cancer-EVs initiated EMT in normal epithelial cells and promoted migration, invasion, and tumorigenesis in oral cancer cells and M2-
like polarity in tumour-associated macrophages. (b) The siRNAs-mediated triple silencing of CDC37/HSP90α/HSP90β diminished EMT
markers in oral cancer cells. The HSP90-depleted EVs-reduced activities for transmission and pro-malignancy in recipient cells.
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chaperone knockdown, also suggesting that the num-
ber of EVs (or exosomes) that contained HSP90, CD9
and CD63 might be reduced by this targeting, while the
other components must be increased instead. Such
a loss of tumour-promoting EVs can be a mechanism
by which triple chaperone knockdown effectively inhi-
bits protumorigenic events and EV uptake by
macrophages.
In conclusion, we have demonstrated that the
siRNA-mediated triple silencing of CDC37/HSP90α/
HSP90β could potentially lead to a novel therapeutic
strategy for attenuating cancer EV-driven macrophage
M2 polarization, EMT, migration, invasion and tumor-
igenesis. We also unveiled the novel finding that the
triple chaperone depletion weakens the EV transmis-
sion activity required for pro-tumorigenic cell-cell
communication in the tumour microenvironment.
Acknowledgments
This paper is dedicated to the memory of one of our mentors,
Professor Ken-ichi Kozaki, who passed away on 29 May 2016.
The authors thank Haruo Urata for the operation of TEM,
Tomonari Kasai and Masaharu Seno for particle size analysis
using ELS-8000, Kazuko Kobayashi for the operation of
Zetasizer, Eriko Aoyama for maintenance of HCS analyzer.
The authors thank Manabu Itoh and Kazuya Arai at JSR for
technical advice in NCP. The authors thank Keisuke Nakano
for illuminating discussion and encouraging support.
Funding
This work was supported by JSPS KAKENHI, grant numbers
[17K11642 (T.E.), 17K11643 (C.S., T.E.), 17K11669 (K.Oh.,
T.E.), 19K24072 (K.On.), 16K11722-JM (T.E., H.N.),
19K10288-JM (H.N.), 18K09789-KN (H.N., T.E),
JP16K11441 (H.N.), JP20H03888 (H.N., T.E.), 19H03817
(M.T., T.E.), 19H04051 (H.O., T.E.) and 20K09904 (C.S., T.
E., K.Ok.)], Ryobi Teien Memorial Foundation Grant (K.Ok.,
C.S., T.E.), Suzuken Memorial Foundation Grant (T.E.) and
NIH Grant CA176326-05 (SKC).
Author contributions
TE, KOn and SKC conceptualized and administrated the
study. TE acquired funding. HN, AS, KK, MT, KOk, HO,
SI and TE prepared resources. TE, CS, MTT, HK, KOn, KK,
HO and KK devised methodology. KOn, HK, MTT, EAT,
YL, YO, CS and MWO performed the experimentation.
KOn, HK, TE, MTT and CS curated, validated and visualized
data. TE, CS, KOk, HO and KK supervised. TE, KOn and HK
wrote the original draft. TE and SKC reviewed and edited,
and revised the manuscript. All authors reviewed the
manuscript.
Competing financial interests




[1] Thery C, Witwer KW, Aikawa E, et al. Minimal infor-
mation for studies of extracellular vesicles 2018
(MISEV2018): a position statement of the international
society for extracellular vesicles and update of the
MISEV2014 guidelines. J Extracell Vesicles. 2018;7
(1):1535750.
[2] Colombo M, Raposo G, Thery C. Biogenesis, secretion,
and intercellular interactions of exosomes and other
extracellular vesicles. Annu Rev Cell Dev Biol.
2014;30:255–289.
[3] van Niel G, D’Angelo G, Raposo G. Shedding light on
the cell biology of extracellular vesicles. Nat Rev Mol
Cell Biol. 2018 Apr;19(4):213–228.
[4] Seyama M, Yoshida K, Yoshida K, et al. Outer mem-
brane vesicles of Porphyromonas gingivalis attenuate
insulin sensitivity by delivering gingipains to the liver.
Biochim Biophys Acta Mol Basis Dis. 2020 Feb 20;1866
(6):1–12.
[5] Okusha Y, Eguchi T, Tran MT, et al. Extracellular
vesicles enriched with moonlighting metalloproteinase
are highly transmissive, pro-tumorigenic, and
trans-activates cellular communication network factor
(CCN2/CTGF): CRISPR against cancer. Cancers
(Basel). 2020;12(4):1–27.
[6] Hoshino A, Costa-Silva B, Shen TL, et al. Tumour
exosome integrins determine organotropic metastasis.
Nature. 2015 Nov 19;527(7578):329–335.
[7] Franzen CA, Blackwell RH, Todorovic V, et al.
Urothelial cells undergo epithelial-to-mesenchymal
transition after exposure to muscle invasive bladder
cancer exosomes. Oncogenesis. 2015 Aug;17(4):e163.
[8] Fujiwara T, Eguchi T, Sogawa C, et al. Carcinogenic
epithelial-mesenchymal transition initiated by oral can-
cer exosomes is inhibited by anti-EGFR antibody
cetuximab. Oral Oncol. 2018;86:251–257.
[9] Clayton A, Turkes A, Navabi H, et al. Induction of heat
shock proteins in B-cell exosomes. J Cell Sci. 2005 Aug
15;118(Pt 16):3631–3638.
[10] Eguchi T, Sogawa C, Ono K, et al. Cell stress induced
stressome release including damaged membrane vesicles
and extracellular HSP90 by prostate cancer cells. Cells.
2020;9(3):1–24.
[11] Eguchi T, Ono K, Kawata K. Regulatory roles of HSP90-
Rich extracellular vesicles. In: Asea AAA and Kaur P,
editors. heat shock protein 90 in human diseases and
disorders. Heat shock proteins. Vol. 19. Cham,
Swizerland: Springer Nature; 2019. p. 3–17.
[12] Ono K, Eguchi T, Sogawa C, et al. HSP-enriched prop-
erties of extracellular vesicles involve survival of meta-
static oral cancer cells. J Cell Biochem. 2018 Sep;119
(9):7350–7373.
18 K. ONO ET AL.
[13] Eguchi T, Sogawa C, Okusha Y, et al. Organoids with
cancer stem cell-like properties secrete exosomes and
HSP90 in a 3D nanoenvironment. Plos One. 2018 Feb
7;13(2):e0191109.
[14] Calderwood SK. Molecular cochaperones: tumor
growth and cancer treatment. Scientifica (Cairo).
2013;2013:217513.
[15] Neckers L. Hsp90 inhibitors as novel cancer che-
motherapeutic agents. Trends Mol Med. 2002;8(4
Suppl):S55–61.
[16] Whitesell L, Lindquist SL. HSP90 and the chaperoning
of cancer. Nat Rev Cancer. 2005 Oct;5(10):761–772.
[17] Taha EA, Ono K, Eguchi T. Roles of extracellular HSPs
as biomarkers in immune surveillance and immune
evasion [Review]. Int J Mol Sci. 2019 Sep 17;20
(18):1–32.
[18] Eustace BK, Sakurai T, Stewart JK, et al. Functional
proteomic screens reveal an essential extracellular role
for hsp90 alpha in cancer cell invasiveness. Nat Cell
Biol. 2004 6;Jun(6):507–514.
[19] Nolan KD, Franco OE, Hance MW, et al. Tumor-
secreted Hsp90 subverts polycomb function to drive
prostate tumor growth and invasion. J Biol Chem.
2015 Mar 27;290(13):8271–8282.
[20] Hance MW, Dole K, Gopal U, et al. Secreted Hsp90 is
a novel regulator of the epithelial to mesenchymal tran-
sition (EMT) in prostate cancer. J Biol Chem. 2012 Nov
02;287(45):37732–37744.
[21] Yilmaz M, Christofori G. EMT, the cytoskeleton, and
cancer cell invasion. Cancer Metastasis Rev. 2009 Jun;28
(1–2):15–33.
[22] Mani SA, Guo W, Liao MJ, et al. The
epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell. 2008 May 16;133
(4):704–715.
[23] Fujiwara T, Eguchi T, Sogawa C, et al. Anti-EGFR anti-
body cetuximab is secreted by oral squamous cell carci-
noma and alters EGF-driven mesenchymal transition.
Biochem Biophys Res Commun. 2018;503
(3):1267–1272. 2018 Available online 13 July.
[24] Eguchi T, Taha EA, Calderwood SK, et al. A novel
model of cancer drug resistance: oncosomal release of
cytotoxic and antibody-based drugs [Review]. Biology
(Basel). 2020 Mar 5;9(3):1–22.
[25] Zheng X, Carstens JL, Kim J, et al. Epithelial-to-
mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer.
Nature. 2015 Nov 26;527(7579):525–530.
[26] Nieto MA, Huang RY, Jackson RA, et al. Emt: 2016.
Cell. 2016 Jun 30;166(1):21–45.
[27] Blackwell RH, Foreman KE, Gupta GN. The role of
cancer-derived exosomes in tumorigenicity & epithelial-
to-mesenchymal transition. Cancers (Basel). 2017. 10. 9
(8):Aug.
[28] Gray PJ, Prince T, Cheng J, et al. Targeting the onco-
gene and kinome chaperone CDC37. Nat Rev Cancer.
2008;8:491–495.
[29] Gray PJ Jr., Stevenson MA, Calderwood SK. Targeting
Cdc37 inhibits multiple signaling pathways and induces
growth arrest in prostate cancer cells. Cancer Res. 2007
Dec 15;67(24):11942–11950.
[30] Calderwood SK. Cdc37 as a co-chaperone to Hsp90.
Subcell Biochem. 2015;78:103–112.
[31] Kimura Y, Rutherford SL, Miyata Y, et al. Cdc37 is
a molecular chaperone with specific functions in signal
transduction. Genes Dev. 1997;11:1775–1785.
[32] Roe SM, Ali MMU, Meyer P, et al. The mechanism of
Hsp90 regulation by the protein kinase-specific cocha-
perone p50 cdc37. Cell. 2004;116:87–98.
[33] Chua HL, Bhat-Nakshatri P, Clare SE, et al. NF-kappaB
represses E-cadherin expression and enhances epithelial
to mesenchymal transition of mammary epithelial cells:
potential involvement of ZEB-1 and ZEB-2. Oncogene.
2007 Feb 01;26(5):711–724.
[34] Wu Y, Deng J, Rychahou PG, et al. Stabilization of snail
by NF-kappaB is required for inflammation-induced cell
migration and invasion. Cancer Cell. 2009 May 05;15
(5):416–428.
[35] Li CW, Xia W, Huo L, et al. Epithelial-mesenchymal
transition induced by TNF-alpha requires NF-kappaB-
mediated transcriptional upregulation of Twist1. Cancer
Res. 2012 Mar 01;72(5):1290–1300.
[36] Murray PJ, Wynn TA. Protective and pathogenic func-
tions of macrophage subsets. Nat Rev Immunol. 2011
Oct 14;11(11):723–737.
[37] Lan J, Sun L, Xu F, et al. M2 macrophage-derived
exosomes promote cell migration and invasion in
colon cancer. Cancer Res. 2019 Jan 1;79(1):146–158.
[38] Wang X, Luo G, Zhang K, et al. Hypoxic tumor-derived
exosomal miR-301a mediates M2 macrophage polariza-
tion via PTEN/PI3Kgamma to promote pancreatic cancer
metastasis. Cancer Res. 2018 Aug 15;78(16):4586–4598.
[39] Zheng P, Chen L, Yuan X, et al. Exosomal transfer of
tumor-associated macrophage-derived miR-21 confers
cisplatin resistance in gastric cancer cells. J Exp Clin
Cancer Res. 2017 Apr 13;36(1):53.
[40] Taha EA, Lu Y, Eguchi T. Exosomes“The little thing
that matter the most”in tumor immunology and micro-
environment. In: kagiya T, editor. Exosomes and micro-
vesicles: role in disease and clinical applications.
Hauppauge, New York: Nova Science Publishers; 2020.
[41] Wang F, Li B, Wei Y, et al. Tumor-derived exosomes
induce PD1(+) macrophage population in human gas-
tric cancer that promotes disease progression.
Oncogenesis. 2018 May 25;7(5):41.
[42] Pirila E, Vayrynen O, Sundquist E, et al. Macrophages
modulate migration and invasion of human tongue
squamous cell carcinoma. PLoS One. 2015;10(3):
e0120895.
[43] Ono K, Eguchi T, Sogawa C, et al. HSP-enriched prop-
erties of extracellular vesicles involve survival of meta-
static oral cancer cells. J Cell Biochem. 2018 May 16;119
(9):7350–7362.
[44] Eguchi T, Prince TL, Tran MT, et al. MZF1 and
SCAND1 Reciprocally Regulate CDC37 Gene
Expression in Prostate Cancer. Cancers (Basel). 2019
Jun 8;11(6):1–15.
[45] Namba Y, Sogawa C, Okusha Y, et al. Depletion of lipid
efflux pump ABCG1 triggers the intracellular accumula-
tion of extracellular vesicles and reduces aggregation
and tumorigenesis of metastatic cancer cells. Front
Oncol. 2018;8(376):1–16.
JOURNAL OF EXTRACELLULAR VESICLES 19
[46] Taha EA, Sogawa C, Okusha Y, et al. Knockout of
MMP3 weakens solid tumor organoids and cancer extra-
cellular vesicles. Cancers, in press.
[47] Lai CP, Kim EY, Badr CE, et al. Visualization and
tracking of tumour extracellular vesicle delivery and
RNA translation using multiplexed reporters. Nat
Commun. 2015 May;13(6):7029.
[48] Lai CP, Mardini O, Ericsson M, et al. Dynamic biodis-
tribution of extracellular vesicles in vivo using
a multimodal imaging reporter. ACS Nano. 2014 Jan
28;8(1):483–494.
[49] Eguchi T, Kubota S, Kawata K, et al. Novel
transcription-factor-like function of human matrix
metalloproteinase 3 regulating the CTGF/CCN2 gene.
Mol Cell Biol. 2008 Apr;28(7):2391–2413.
[50] Arai K, Eguchi T, Rahman MM, et al. A novel
high-throughput 3D screening system for EMT inhibitors:
a pilot screening discovered the EMT inhibitory activity of
CDK2 inhibitor SU9516. PLoS One. 2016;11(9):e0162394.
[51] Sogawa C, Eguchi T, Tran MT, et al. Antiparkinson
drug benztropine suppresses tumor growth, circulating
tumor cells, and metastasis by acting on SLC6A3/DAT
and reducing STAT3. Cancers (Basel). 2020;12(2):1–22.
[52] Sogawa C, Eguchi T, Okusha Y, et al. A reporter system
evaluates tumorigenesis, metastasis, beta-catenin/MMP
regulation, and druggability. Tissue Eng Part A. 2019
Feb 8;25(19–20):1413–1425.
[53] Yoshida S, Kawai H, Eguchi T, et al. Tumor angiogenic
inhibition triggered necrosis (TAITN) in oral cancer.
Cells. 2019 Jul 22;8(7):1–15.
[54] Okusha Y, Eguchi T, Sogawa C, et al. The intranuclear
PEX domain of MMP involves proliferation, migration,
and metastasis of aggressive adenocarcinoma cells. J Cell
Biochem. 2018 Sep;119(9):7363–7376.
[55] Eguchi T, Sogawa C, Ono K, et al. CDC37 and HSP90
are essential for stressome release and tumor progres-
sion in resistant prostate cancer. 11 February
2020 by MDPI (Preprints). doi:10.20944/pre-
prints202002.0148.v1.
[56] Litvinov SV, Velders MP, Bakker HA, et al. Ep-CAM:
a human epithelial antigen is a homophilic cell-cell
adhesion molecule. J Cell Biol. 1994 Apr;125
(2):437–446.
[57] Munz M, Baeuerle PA, Gires O. The emerging role of
EpCAM in cancer and stem cell signaling. Cancer Res.
2009 Jul 15;69(14):5627–5629.
[58] Zona L, Tawar RG, Zeisel MB, et al. CD81-receptor
associations–impact for hepatitis C virus entry and anti-
viral therapies. Viruses. 2014 Feb 18;6(2):875–892.
[59] van Niel G, Charrin S, Simoes S, et al. The tetraspanin
CD63 regulates ESCRT-independent and -dependent
endosomal sorting during melanogenesis. Dev Cell.
2011 Oct 18;21(4):708–721.
[60] Pols MS, Klumperman J. Trafficking and function of the
tetraspanin CD63. Exp Cell Res. 2009 May 15;315
(9):1584–1592.
[61] Li W, Li Y, Guan S, et al. Extracellular heat shock
protein-90alpha: linking hypoxia to skin cell motility
and wound healing. Embo J. 2007 Mar 7;26
(5):1221–1233.
[62] de la Mare JA, Jurgens T, Edkins AL. Extracellular
Hsp90 and TGFbeta regulate adhesion, migration and
anchorage independent growth in a paired colon can-
cer cell line model. BMC Cancer. 2017 Mar 16;17
(1):202.
[63] Capaldo CT, Nusrat A. Claudin switching: physiological
plasticity of the Tight Junction. Semin Cell Dev Biol.
2015 Jun;42:22–29.
[64] Le Naour F, Zoller M. The tumor antigen EpCAM:
tetraspanins and the tight junction protein claudin-7,
new partners, new functions. Front Biosci. 2008 May
1;13:5847–5865.
[65] Luo Y, Zhou H, Krueger J, et al. Targeting
tumor-associated macrophages as a novel strategy
against breast cancer. J Clin Invest. 2006 Aug;116
(8):2132–2141.
[66] Sung BH, Ketova T, Hoshino D, et al. Directional cell
movement through tissues is controlled by exosome
secretion. Nat Commun. 2015 May;13(6):7164.
[67] Ham S, Lima LG, Chai EPZ, et al. Breast cancer-derived
exosomes alter macrophage polarization via gp130/
STAT3 Signaling. Front Immunol. 2018;9:871.
[68] Kanlikilicer P, Bayraktar R, Denizli M, et al. Exosomal
miRNA confers chemo resistance via targeting Cav1/
p-gp/M2-type macrophage axis in ovarian cancer.
EBioMedicine. 2018;38:100–112.
[69] de Vrij J, Maas SL, Kwappenberg KM, et al.
Glioblastoma-derived extracellular vesicles modify the
phenotype of monocytic cells. Int J Cancer. 2015 Oct
1;137(7):1630–1642.
[70] Fujii N, Shomori K, Shiomi T, et al. Cancer-associated
fibroblasts and CD163-positive macrophages in oral
squamous cell carcinoma: their clinicopathological and
prognostic significance. J Oral Pathol Med. 2012 Jul;41
(6):444–451.
[71] Calderwood SK, Gong J, Murshid A. Extracellular HSPs:
the Complicated Roles of Extracellular HSPs in
Immunity. Front Immunol. 2016;7:159.
[72] Murshid A, Gong J, Calderwood SK. Hsp90-peptide
complexes stimulate antigen presentation through the
class II pathway after binding scavenger receptor
SREC-I. Immunobiology. 2014 Dec;219(12):924–931.
[73] Furuta K, Eguchi T. Roles of heat shock proteins on
antigen presentation. In: Asea AAA, Kaur P, editors.
Heat shock proteins in cancer therapeutics. heat shock
proteins. 2020, in press. Cham, Switzerland: Springer
Nature.
[74] Udono H, Srivastava PK. Comparison of tumor-specific
immunogenicities of stress-induced proteins gp96,
hsp90, and hsp70. J Immunol. 1994 Jun 1;152
(11):5398–5403.
[75] Basu S, Binder RJ, Ramalingam T, et al. CD91 is
a common receptor for heat shock proteins gp96,
hsp90, hsp70, and calreticulin. Immunity. 2001 Mar;14
(3):303–313.
[76] Murshid A, Gong J, Calderwood SK. Heat shock protein
90 mediates efficient antigen cross presentation through
the scavenger receptor expressed by endothelial cells-I.
J Immunol. 2010 Sep 1;185(5):2903–2917.
[77] Murshid A, Borges TJ, Bonorino C, et al.
Immunological outcomes mediated upon binding of
heat shock proteins to scavenger receptors SCARF1
and LOX-1, and endocytosis by mononuclear
phagocytes. Front Immunol. 2019;10:3035.
20 K. ONO ET AL.
[78] Saha B, Momen-Heravi F, Furi I, et al. Extracellular
vesicles from mice with alcoholic liver disease carry
a distinct protein cargo and induce macrophage activa-
tion through heat shock protein 90. Hepatology. 2018
May;67(5):1986–2000.
[79] Hemler ME. Tetraspanin proteins promote multiple
cancer stages. Nat Rev Cancer. 2014 Jan;14(1):49–60.
[80] Charrin S, Jouannet S, Boucheix C, et al. Tetraspanins
at a glance. J Cell Sci. 2014 Sep 1;127(Pt
17):3641–3648.
JOURNAL OF EXTRACELLULAR VESICLES 21
